|
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z # |
Apixaban
Test Code94223
CPT Codes
80299<br /> **This test is not available for New York patient testing.**
Preferred Specimen
1 mL platelet-poor plasma submitted in a 3.2% sodium citrate (light blue-top) tube
Minimum Volume
0.5 mL
Instructions
Follow current CLSI guidelines for obtaining platelet-poor plasma
Transport Temperature
Frozen
Specimen Stability
Room temperature: Unacceptable
Refrigerated: Unacceptable
Frozen: 28 days
Refrigerated: Unacceptable
Frozen: 28 days
Reject Criteria (Eg, hemolysis? Lipemia? Thaw/Other?)
Clotted • Hemolysis • Icteric • Grossly lipemic
Methodology
Chromogenic
FDA Status
This test was developed and its analytical performance characteristics have been determined by Quest Diagnostics. It has not been cleared or approved by the FDA. This assay has been validated pursuant to the CLIA regulations and is used for clinical purposes.
Setup Schedule
AM
Reference Range
See Laboratory Report
Clinical Significance
Apixaban is an oral factor Xa inhibitor that is indicated to reduce the risk of stroke and systemic embolism in patients with nonvalvular atrial fibrillation. It is also indicated for the treatment, prophylaxis, or the reduction in the risk of recurrence of deep vein thrombosis (DVT) or pulmonary embolism (PE). Apixaban does not need to be monitored routinely, however, exceptions may include determination of failure of therapy vs. poor compliance, or potential dose adjustment required for renal or hepatic dysfunction.